Latest Tyrosine kinase Stories
Research Presented at 2015 Gastrointestinal Cancers Symposium Highlights Clinical Utility of Caris Molecular Intelligence IRVING, Texas, Jan.
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc.
WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
SAN DIEGO, Sept. 4, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
-- Anti-EphA3 Agents Inhibit Tumor Growth by Disrupting or Destroying the Tumor Microenvironment: Malignant Stem Cells, Stromal Cells, and New Tumor Vasculature -- SOUTH SAN FRANCISCO, Calif.,
Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug.
SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL).
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.
- A volcanic mudflow.